Thursday, February 7, 8:30 – 10:00 AM
Location To Be Determined
How can Finland become more attractive for R&D and innovation investment? How can we make the Finnish healthcare platform more friendly to companies?
Market access for life science companies is of concern. It may currently take up to three years for innovative medicines to get approval for a government reimbursement program in Finland. This same process is often completed in a matter of months throughout other European countries. Shortening this timeframe will help businesses prosper, as well as benefit patients in Finland.
Dr. Niels Emmerich, AbbVie’s VP and Global Head of Search & Evaluation, will be visiting Finland to discuss policy regulations and the business climate for life science companies.
Päivi Sillanaukee, Permanent Secretary at Ministry of Social Affairs and Health, will give opening remarks.
More info coming soon!
Permanent Secretary at Ministry of Social Affairs and Health
Dr. Niels Emmerich
Vice President, Global Head of Search and Evaluation at AbbVie
For more information contact:
+358 50 430 3443